Ernexa Therapeutics (ERNAW) Income from Continuing Operations (2010 - 2026)
Ernexa Therapeutics (ERNAW) reported Income from Continuing Operations of 5506000.0 for Q1 2026, up 32.87% on a YoY basis from 4143899.06 in Q1 2025, and down 255.23% quarter-over-quarter from 1550000.0 in Q4 2025.
Ernexa Therapeutics (ERNAW) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Ernexa Therapeutics has reported Income from Continuing Operations for 17 years, with the latest figure at 5506000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 32.87% year-over-year to 5506000.0; the trailing twelve-month figure through Mar 2026 stood at 11435000.0 (down 643.5% YoY), and the FY2025 full-year result was 14132000.0, down 83229.41% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 5506000.0, down from 1550000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 38797000.0 in Q4 2024, with the low at 26604000.0 in Q3 2024.
- Historically, Income from Continuing Operations has averaged 3871058.82 across 5 years, with a median of 5506000.0 in 2026.
- The largest YoY upside for Income from Continuing Operations was 732.28% in 2024 against a maximum downside of 375.84% in 2024.
- Ernexa Therapeutics' Income from Continuing Operations stood at 4448000.0 in 2022, then sank by 37.95% to 6136000.0 in 2023, then surged by 732.28% to 38797000.0 in 2024, then tumbled by 104.0% to 1550000.0 in 2025, then plunged by 255.23% to 5506000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 5506000.0 (Q1 2026), 1550000.0 (Q4 2025), and 1240000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Ernexa Therapeutics | - | - | - | -5.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.51 Mn |
| Dec 31, 2025 | -1.55 Mn |
| Sep 30, 2025 | -1.24 Mn |
| Jun 30, 2025 | -3.14 Mn |
| Mar 31, 2025 | -8.20 Mn |
| Dec 31, 2024 | 38.80 Mn |
| Sep 30, 2024 | -26.60 Mn |
| Jun 30, 2024 | -5.53 Mn |
| Mar 31, 2024 | -6.65 Mn |
| Dec 31, 2023 | -6.14 Mn |
| Sep 30, 2023 | -5.59 Mn |
| Jun 30, 2023 | -4.51 Mn |
| Mar 31, 2023 | -5.42 Mn |
| Dec 31, 2022 | -4.45 Mn |
| Sep 30, 2022 | -7.32 Mn |
| Jun 30, 2022 | -3.40 Mn |
| Mar 31, 2022 | -9.38 Mn |
| Dec 31, 2021 | 114.52 Mn |
| Sep 30, 2021 | -85.99 Mn |
| Jun 30, 2021 | -10.01 Mn |